Page last updated: 2024-11-13

neosalacinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID44451613
CHEMBL ID259721
CHEMBL ID1684162
MeSH IDM0538520

Synonyms (4)

Synonym
CHEMBL259721
neosalacinol
CHEMBL1684162 ,
bdbm50338669
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Maltase-glucoamylase, intestinalHomo sapiens (human)IC50 (µMol)9.00000.04003.46529.0000AID1684763
Sucrase-isomaltase, intestinalRattus norvegicus (Norway rat)IC50 (µMol)2.72000.04001.848310.0000AID324678; AID324679; AID324680; AID578320; AID578321; AID594100; AID594101
Glycogen debranching enzymeHomo sapiens (human)IC50 (µMol)16.00008.40009.514310.0000AID324673
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)IC50 (µMol)8.00000.08002.50619.8500AID578319; AID594099
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
glycogen biosynthetic processGlycogen debranching enzymeHomo sapiens (human)
glycogen catabolic processGlycogen debranching enzymeHomo sapiens (human)
response to nutrientGlycogen debranching enzymeHomo sapiens (human)
response to glucocorticoidGlycogen debranching enzymeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glycogen debranching enzyme activityGlycogen debranching enzymeHomo sapiens (human)
4-alpha-glucanotransferase activityGlycogen debranching enzymeHomo sapiens (human)
amylo-alpha-1,6-glucosidase activityGlycogen debranching enzymeHomo sapiens (human)
protein bindingGlycogen debranching enzymeHomo sapiens (human)
polysaccharide bindingGlycogen debranching enzymeHomo sapiens (human)
polyubiquitin modification-dependent protein bindingGlycogen debranching enzymeHomo sapiens (human)
beta-maltose 4-alpha-glucanotransferase activityGlycogen debranching enzymeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular regionGlycogen debranching enzymeHomo sapiens (human)
nucleusGlycogen debranching enzymeHomo sapiens (human)
cytoplasmGlycogen debranching enzymeHomo sapiens (human)
cytosolGlycogen debranching enzymeHomo sapiens (human)
inclusion bodyGlycogen debranching enzymeHomo sapiens (human)
sarcoplasmic reticulumGlycogen debranching enzymeHomo sapiens (human)
secretory granule lumenGlycogen debranching enzymeHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen debranching enzymeHomo sapiens (human)
isoamylase complexGlycogen debranching enzymeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1684764Inhibition of rat intestinal isomaltase using isomaltose as substrate incubated for 30 mins and immediately heated for 2 mins by glucose oxidase method2021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine "Salacia," against human intestinal maltase.
AID1684766Inhibition of rat intestinal maltase using maltose as substrate incubated for 30 mins and immediately heated for 2 mins by glucose oxidase method2021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine "Salacia," against human intestinal maltase.
AID578320Inhibition of rat intestinal sucrase2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.
AID594101Inhibition of rat small intestinal isomaltase after 30 mins by glucose-oxidase method2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Biological evaluation of 3'-O-alkylated analogs of salacinol, the role of hydrophobic alkyl group at 3' position in the side chain on the α-glucosidase inhibitory activity.
AID493815Inhibition of alpha glucosidase2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Docking and SAR studies of salacinol derivatives as alpha-glucosidase inhibitors.
AID594100Inhibition of rat small intestinal sucrase after 30 mins by glucose-oxidase method2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Biological evaluation of 3'-O-alkylated analogs of salacinol, the role of hydrophobic alkyl group at 3' position in the side chain on the α-glucosidase inhibitory activity.
AID578321Inhibition of rat intestinal isomaltase2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.
AID1684765Inhibition of rat intestinal sucrase using sucrose as substrate incubated for 30 mins and immediately heated for 2 mins by glucose oxidase method2021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine "Salacia," against human intestinal maltase.
AID594099Inhibition of rat small intestinal maltase after 30 mins by glucose-oxidase method2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Biological evaluation of 3'-O-alkylated analogs of salacinol, the role of hydrophobic alkyl group at 3' position in the side chain on the α-glucosidase inhibitory activity.
AID578319Inhibition of rat intestinal maltase2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.
AID1684763Inhibition of human intestinal maltase using maltose as substrate incubated for 30 mins and immediately heated for 2 mins by glucose oxidase method2021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine "Salacia," against human intestinal maltase.
AID324681Inhibition of human lysosomal alpha glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID324673Inhibition of amylo-1,6-glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID324677Inhibition of yeast alpha-glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID324672Inhibition of rabbit muscle glycogen phosphorylase b at 400 uM2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID324679Inhibition of rat isomaltase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID324680Inhibition of rat sucrase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID324676Inhibition of rice alpha-glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID324683Inhibition of maltase in human Caco-2 cell membrane at 1 uM2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
AID324678Inhibition of rat intestinal maltase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Effect of five-membered sugar mimics on mammalian glycogen-degrading enzymes and various glucosidases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]